Study identifier:D7413R00001
ClinicalTrials.gov identifier:NCT06099236
EudraCT identifier:N/A
CTIS identifier:N/A
A prospective, non-interventional, observational study of presentation, treatment patterns and outcomes in Chinese Atypical Hemolytic Uremic Syndrome patients
Atypical Hemolytic Uremic Syndrome(aHUS)
Phase 4
No
-
All
1070
Observational
n/a - n/a
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Apr 2025 by AstraZeneca
AstraZeneca
-
This is a China, non-interventional, observational study and will follow the Good Phar-macoepidemiology Practices guidelines. This study will enrol paediatric and adult patients diagnosed with aHUS who will be treated according to routine clinical practice defined by local institutional treatment guidelines/protocol. Those aHUS patients who will be treated with a supportive therapy, which does not contain eculizumab, will be monitored for up to 12 months since the ini-tial diagnosis. Patients initiated on eculizumab treatment anytime between aHUS diagno-sis until 12 months will be followed for additional 12 months, starting from the ecu initia-tion. Patient disposition, characteristics, outcomes and safety will be described for all pa-tients enrolled into this study
Location
Status
Location
Nanchang, China
Status
Recruiting
Location
Beijing, China
Status
Active, not recruiting
Location
Shijiazhuang, Heibei, China
Status
Not yet recruiting
Location
Luzhou, Sichuan, China
Status
Active, not recruiting
Location
Beijing, Beijing, China
Status
Active, not recruiting
Location
Shenyang, China
Status
Active, not recruiting
Location
Xuzhou, China
Status
Active, not recruiting
Location
Suzhou, China
Status
Active, not recruiting
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.